WuXi Biologics Achieves Highest Negligible-Risk ESG Rating
WuXi Biologics, a prominent global organization in Contract Research, Development, and Manufacturing (CRDMO), has made headlines by securing the highest negligible-risk tier in the ESG rating system developed by Morningstar Sustainalytics. This accolade, announced on July 16, 2025, underscores the company’s commitment to sustainability and strong governance in the pharmaceutical sector.
The Morningstar Sustainalytics ESG Risk Ratings assess thousands of companies worldwide based on their exposure to a variety of environmental, social, and governance issues. Each company is rated against over 200 indicators that evaluate their ESG efforts, placing them into one of five risk levels from negligible to severe. WuXi Biologics not only achieved the lowest risk exposure but also received the highest marks for risk management, situating the firm within the top 1% of companies in its category globally.
Success in Sustainability
This is not the first instance that WuXi Biologics has been recognized for its commitment to sustainable practices. The firm has been identified as the Industry and Regional ESG Top-Rated Company for five consecutive years, solidifying its status as a leader in green CRDMO solutions. Dr. Chris Chen, the CEO of WuXi Biologics and the Chairman of the ESG Committee, expressed pride in this achievement, stating, "It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities."
Dr. Chen emphasized that their focus extends beyond internal practices; the company's mission is to enable their partners globally to achieve their own ESG objectives, demonstrating a dedication to fostering sustainable practices throughout the entire value chain.
Recognitions and Accreditations
As part of its sustainability journey, WuXi Biologics has joined multiple initiatives and organizations aimed at advancing global sustainability goals. It is a member of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), actively engaging in discussions surrounding sustainable development. Furthermore, the company boasts an MSCI AAA rating, an EcoVadis Platinum Medal, and has been consistently listed in the Dow Jones Sustainability Indices. Additionally, WuXi Biologics is recognized as a Constituent of the FTSE4Good Index Series and appears in the Hang Seng ESG 50 Index, thanks to its continued excellence in environmental performance.
A Vision for a Sustainable Future
WuXi Biologics believes that sustainability is crucial to the long-term growth of the business. With over 12,000 skilled employees working across five countries, the organization is not only a significant player in biologic research and manufacturing but also an advocate for green technology innovations. By providing advanced CRDMO solutions, WuXi Biologics aims to support its partners’ quest for a greener future. They also strive to create shared value by collaborating with various stakeholders to generate positive social and environmental impacts.
The commitment to fostering responsible practices allows the entire value chain to thrive, creating a ripple effect of sustainability that impacts patients and the environment alike.
With its innovative approaches and dedication to sustainable practices, WuXi Biologics is undoubtedly setting the benchmark for ESG excellence in the global pharmaceutical industry. To learn more about their initiatives and contributions toward a sustainable future, visit
WuXi Biologics.